Global Osteoporosis Drugs Market 2015-2019

骨粗鬆症治療薬の世界市場2015-2019

◆タイトル:Global Osteoporosis Drugs Market 2015-2019
◆商品コード:IRTNTR5759
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年5月6日
◆ページ数:84
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five User(5名使用)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、骨粗鬆症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、骨粗鬆症治療薬の世界市場規模及び予測、治療クラス別分析、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About osteoporosis
Osteoporosis, or porous bone, is a disease characterized by low bone density and structural deterioration of bone tissue, leading to fragile bones. As bones becomes fragile, risk of fracture increases. Osteoporosis primarily affects women, but can also affect men. In women, bone loss occurs rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement is too slow. Risk factors for osteoporosis include gender, age, low body weight, ethnicity, and family history. Some of the risk factors that can be manipulated include sex hormones, medication use, intake of calcium and vitamins, alcohol intake, and smoking.

Technavio’s analysts forecast the global osteoporosis drugs market to grow at a CAGR of 4.14 percent over the period 2014-2019.

[Covered in this report]
This report covers the present scenario and the growth prospects of the global osteoporosis drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs, including products with approved labeling and generic versions.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global osteoporosis drugs market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, clinical stage pipeline molecules developed for the treatment of osteoporosis are discussed.

Technavio’s report, Global Osteoporosis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC; it also covers the global osteoporosis drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions
• Americas
• APAC
• EMEA

Key vendors
• Amgen
• Eli Lilly
• Merck
• Novartis

Other prominent vendors
• Abiogen Pharma
• Deltanoid Pharmaceuticals
• F. Hoffmann La Roche
• GlaxoSmithKline
• IMMD
• Ligand Pharmaceuticals
• NPS Pharma
• Pantarhei Bioscience
• Pfizer
• PhytoHealth
• Radius Health
• UPSHER-SMITH LABORATORIES
• Zosano Pharma

Market driver
• Increase in aging population
• For a full, detailed list, view our report

Market challenge
• Multiple expiries of patents
• For a full, detailed list, view our report

Market trend
• Increase in awareness about bone health
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding Osteoporosis
06.2 Epidemiology and Demography
06.3 Risk Factors
06.4 Symptoms
06.5 Diagnosis
06.6 Treatment

07.Key Development in Osteoporosis Therapy

08.Market Landscape
08.1 Market Overview
08.1.1 Market Size and Forecast
08.2 Osteoporosis Drugs Market in US
08.2.1 Market Size and Forecast
08.3 Osteoporosis Drugs Market in Europe
08.3.1 Market Size and Forecast
08.4 Five Forces Analysis

09.Market Segmentation by Therapeutic Class
09.1 Global Osteoporosis Drugs Market by Therapeutic Class 2014-2019
09.2 Antiresorptive Medications
09.3 Anabolic Medications

10.Market Segmentation by Line of Therapy
10.1 Global Osteoporosis Drugs Market by Line of Therapy

11.Pipeline Assessment
11.1 Key Information about Pipeline Candidates

12.Geographical Segmentation
12.1 Global Osteoporosis Drugs Market by Geographical Segmentation 2014-2019
12.2 Osteoporosis Drugs Market in Americas
12.2.1 Market Size and Forecast
12.3 Osteoporosis Drugs Market in EMEA
12.3.1 Market Size and Forecast
12.4 Osteoporosis Drugs Market in APAC
12.4.1 Market Size and Forecast

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.1.3 Vendor Ranking 2014
20.1.4 Competitive Assessment of Major Drugs
20.1.5 Amgen
20.1.6 Eli Lilly
20.1.7 Merck
20.1.8 Novartis
20.2 Other Prominent Vendors

21.Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Eli Lilly
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation by Revenue
21.2.4 Sales by Geography
21.2.5 Business Strategy
21.2.6 Key Information
21.2.7 SWOT Analysis
21.3 Merck & Co. Inc.
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2013
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Business Strategy
21.3.7 Key Developments
21.3.8 SWOT Analysis
21.4 Novartis AG
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis

22.Other Reports in this Series
List Of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Interpretation of BMD Results
Exhibit 3: Global Osteoporosis Drugs Market 2014-2019 ($ billion)
Exhibit 4: Osteoporosis Drugs Market in US 2014-2019 ($ billion)
Exhibit 5: Osteoporosis Drugs Market in Europe 2014-2019 ($ billion)
Exhibit 6: Segmentation of Global Osteoporosis Drugs Market by Geography 2014
Exhibit 7: Segmentation of Global Osteoporosis Drugs Market by Geography 2019
Exhibit 8: Osteoporosis Drugs Market in Americas 2014-2019 ($ billion)
Exhibit 9: Osteoporosis Drugs Market in EMEA 2014-2019 ($ billion)
Exhibit 10: Osteoporosis Drugs Market in APAC 2014-2019 ($ billion)
Exhibit 11: Segmentation of Global Osteoporosis Drugs Market by Geography 2014-2019
Exhibit 12: Revenue Comparison of Top Osteoporosis Drugs for First Three Quarters 2014 ($ million)
Exhibit 13: YoY Growth Rate and Global Revenue of Prolia 2010-2013 ($ million)
Exhibit 14: Revenue of Prolia by Country/Region 2010-2013 ($ million)
Exhibit 15: YoY Growth Rate and Global Revenue of Evista 2010-2013 ($ million)
Exhibit 16: Revenue of Evista by Country/Region 2010-2013 ($ million)
Exhibit 17: YoY Growth Rate and Global Revenue of Forteo 2010-2013 ($ million)
Exhibit 18: Revenue of Forteo by Country/Region 2010-2013 ($ million)
Exhibit 19: YoY Growth Rate and Global Revenue of Fosamax 2011-2014 ($ million)
Exhibit 20: YoY Growth Rate and Global Revenue of Reclast/Aclasta 2010-2013 ($ million
Exhibit 21: Revenue of Reclast/Aclasta by Country/Region 2010-2012 ($ million)
Exhibit 22: Amgen: Business Segmentation by Revenue 2013
Exhibit 23: Amgen: Product Portfolio by Revenue 2013
Exhibit 24: Amgen: Business Segmentation by Revenue 2012 and 2013 ($ billion)
Exhibit 25: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 26: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 27: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ million)
Exhibit 28: Eli Lilly: Sales by Geography 2013
Exhibit 29: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 30: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 ($ billion)
Exhibit 31: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 32: Novartis AG: Business Segmentation
Exhibit 33: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 34: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million)
Exhibit 35: Novartis AG: Revenue by Geographical Segmentation 2013



【掲載企業】

Amgen, Eli Lilly, Merck, Novartis, Abiogen Pharma, Deltanoid Pharmaceuticals, F. Hoffmann La Roche, GlaxoSmithKline, IMMD, Ligand Pharmaceuticals, NPS Pharma, Pantarhei Bioscience, Pfizer, PhytoHealth, Radius Health, UPSHER-SMITH LABORATORIES, Zosano Pharma

【資料のキーワード】

骨粗鬆症治療薬、骨形成、医薬品、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[骨粗鬆症治療薬の世界市場2015-2019] (Global Osteoporosis Drugs Market 2015-2019 / IRTNTR5759)販売に関する免責事項
[骨粗鬆症治療薬の世界市場2015-2019] (Global Osteoporosis Drugs Market 2015-2019 / IRTNTR5759)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆